Compare ANIX & AMRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIX | AMRO |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.9M | 105.1M |
| IPO Year | 2013 | 2026 |
| Metric | ANIX | AMRO |
|---|---|---|
| Price | $3.00 | $5.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | 203.7K | ★ 601.2K |
| Earning Date | 09-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | $374.17 |
| Revenue Next Year | N/A | $81.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $3.99 |
| 52 Week High | $5.46 | $8.64 |
| Indicator | ANIX | AMRO |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 59.87 |
| Support Level | $2.77 | $4.25 |
| Resistance Level | $3.09 | $6.60 |
| Average True Range (ATR) | 0.18 | 1.16 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 47.65 | 36.78 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.